With its factory utilization rates reaching 70-80%, polarizer manufacturer Cheng Mei Materials Technology (CMMT) anticipates double-digit sequential revenue growth in the second quarter, driven by new orders from South Korea and China.
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new.
Polarizer supplier CMMT expects modest recovery in 2024 digitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitimes.com Daily Mail and Mail on Sunday newspapers.